Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Leandro L Santos

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
International Journal of Molecular Sciences|April 28, 2023
Modulation of Disease-Associated Pathways in Hidradenitis Suppurativa by the Janus Kinase 1 Inhibitor Povorcitinib: Transcriptomic and Proteomic Analyses of Two Phase 2 StudiesHuiqing Liu, Leandro L Santos, Susan H Smith
Current Protocols in Pharmacology|September 29, 2020
In Vitro Permeation Test (IVPT) for Pharmacokinetic Assessment of Topical Dermatological FormulationsLeandro L Santos, Nathaniel J Swofford, Brandon G Santiago
The British Journal of Dermatology|January 30, 2023
Initial validation of the Hidradenitis Suppurativa Quality of Life tool in a clinical trial settingLeandro L Santos, Zhaoyin Zhu, Kurt Brown, et al.
Journal of Agricultural and Food Chemistry|September 30, 2005
Multielement analysis of soft drinks by X-ray fluorescence spectrometryOrghêda L A D Zucchi, Silvana Moreira, Marcos J Salvador, et al.
International Journal of Pharmaceutics|May 29, 2021
Developability profile framework for lead candidate selection in topical dermatologyLeandro L Santos, Eva L Wu, Kaitlin M Grinias, et al.
The British Journal of Dermatology|January 3, 2022
Janus kinase 1 inhibitor INCB054707 for patients with moderate-to-severe hidradenitis suppurativa: results from two phase II studiesAfsaneh Alavi, Iltefat Hamzavi, Kurt Brown, et al.
Journal of the American Academy of Dermatology|June 15, 2025
Efficacy and safety of the oral Janus kinase 1 inhibitor povorcitinib in patients with extensive vitiligo in a phase 2, randomized, double-blinded, dose-ranging, placebo-controlled studyAmit G Pandya, Khaled Ezzedine, Thierry Passeron, et al.
Journal of the American Academy of Dermatology|October 23, 2023
Efficacy and safety of the oral Janus kinase 1 inhibitor povorcitinib (INCB054707) in patients with hidradenitis suppurativa in a phase 2, randomized, double-blind, dose-ranging, placebo-controlled studyJoslyn S Kirby, Martin M Okun, Afsaneh Alavi, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
International Journal of Molecular Sciences|April 28, 2023
Modulation of Disease-Associated Pathways in Hidradenitis Suppurativa by the Janus Kinase 1 Inhibitor Povorcitinib: Transcriptomic and Proteomic Analyses of Two Phase 2 StudiesHuiqing Liu, Leandro L Santos, Susan H Smith
Current Protocols in Pharmacology|September 29, 2020
In Vitro Permeation Test (IVPT) for Pharmacokinetic Assessment of Topical Dermatological FormulationsLeandro L Santos, Nathaniel J Swofford, Brandon G Santiago
The British Journal of Dermatology|January 30, 2023
Initial validation of the Hidradenitis Suppurativa Quality of Life tool in a clinical trial settingLeandro L Santos, Zhaoyin Zhu, Kurt Brown, et al.
Journal of Agricultural and Food Chemistry|September 30, 2005
Multielement analysis of soft drinks by X-ray fluorescence spectrometryOrghêda L A D Zucchi, Silvana Moreira, Marcos J Salvador, et al.
International Journal of Pharmaceutics|May 29, 2021
Developability profile framework for lead candidate selection in topical dermatologyLeandro L Santos, Eva L Wu, Kaitlin M Grinias, et al.
The British Journal of Dermatology|January 3, 2022
Janus kinase 1 inhibitor INCB054707 for patients with moderate-to-severe hidradenitis suppurativa: results from two phase II studiesAfsaneh Alavi, Iltefat Hamzavi, Kurt Brown, et al.
Journal of the American Academy of Dermatology|June 15, 2025
Efficacy and safety of the oral Janus kinase 1 inhibitor povorcitinib in patients with extensive vitiligo in a phase 2, randomized, double-blinded, dose-ranging, placebo-controlled studyAmit G Pandya, Khaled Ezzedine, Thierry Passeron, et al.
Journal of the American Academy of Dermatology|October 23, 2023
Efficacy and safety of the oral Janus kinase 1 inhibitor povorcitinib (INCB054707) in patients with hidradenitis suppurativa in a phase 2, randomized, double-blind, dose-ranging, placebo-controlled studyJoslyn S Kirby, Martin M Okun, Afsaneh Alavi, et al.
Pageof 1